Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRP-1001 in Facioscapulohumeral Muscular Dystrophy Type 1
NCT06131983Phase 2Enrolling by invitation
- Sponsor
- Sarepta Therapeutics
- Start
- Jun 2024
- Primary completion
- Dec 2028
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 7
01
Overview
A Phase 2 trial of ARO-DUX4 in facioscapulohumeral muscular dystrophy type 1 (FSHD1), sponsored by Sarepta Therapeutics. Started Jun 2024; status: enrolling by invitation.
02
Drugs
ARO-DUX4
03
Conditions
facioscapulohumeral muscular dystrophy type 1 (FSHD1)
Beyond the preview
Go deeper on NCT06131983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06131983.